@article{cf0d49c48ebc4beb959f1ae504bc2c5f,
title = "Industry updates from the field of stem cell research and regenerative medicine in November 2021",
abstract = "Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in November 2021.",
keywords = "industry, regenerative medicine, stem cells",
author = "Dusko Ilic and Mirjana Liovic",
note = "Funding Information: Humanigen (CA, USA; www.humanigen.com), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called {\textquoteleft}cytokine storm{\textquoteright} with its lead drug candidate, lenzilumab, plans to support a phase II/III study to evaluate lenzilumab for the early treatment of acute graft-versus-host disease (aGvHD) following allogeneic hematopoietic stem cell transplantation (HSCT) in collaboration with IMPACT, a world class accelerated trial network delivering innovative research for stem cell transplant patients in the UK [32]. The study is partially funded by IMPACT with Humanigen providing lenzilumab and the remaining funding for the study. Lenzilumab neutralizes the immune signaling protein GM-CSF, which has been shown to initiate the inflammatory cascade that drives aGvHD, a serious condition with significant unmet needs that affects 30–50% of all patients who undergo HSCT. The RATinG study will evaluate lenzilumab in patients who have undergone allogeneic HSCT and been diagnosed with high risk aGvHD. The trial will be conducted at up to 22 sites across the UK transplant network in two stages. The first stage of the study will treat 20 patients with lenzilumab before halting for an interim assessment of safety, efficacy and futility. Funding Information: Pluristem Therapeutics (Israel; www.pluristem.com) has received approval for an additional grant from the Israel Innovation Authority (IIA) to support research based on its cutting edge PLX platform [51]. The grant comes as part of the company{\textquoteright}s work as part of the CRISPR-IL consortium, which the IIA funds through its Bio-Convergence Program. The IIA approved a new budget for the Consortium to continue its work for an additional 18 months ({\textquoteleft}period B{\textquoteright}) after evaluating its activity and results over the past 18 months ({\textquoteleft}period A{\textquoteright}). Publisher Copyright: {\textcopyright} 2022 Future Medicine Ltd.",
year = "2022",
month = mar,
day = "1",
doi = "10.2217/rme-2022-0004",
language = "English",
volume = "17",
pages = "107--117",
journal = "Regenerative medicine",
issn = "1746-0751",
publisher = "Future Medicine",
number = "3",
}